NAT2 and hepatocellular carcinoma: Reduced NAT2 activity has been associated with increased susceptibility to certain diseases, such as systemic lupus erythematosus, some types of cancer (hepatocellular carcinoma, bladder cancer, etc.)and increased toxicity to some drugs, such as isoniazid and hydralazine [20].